Cambridge Cognition (LON:COG) Share Price Passes Above 200-Day Moving Average – What’s Next?

Cambridge Cognition Holdings Plc (LON:COG)’s stock price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 34.50 and traded as high as GBX 38. Cambridge Cognition shares last traded at GBX 36.88, with a volume of 3,119 shares trading hands.

Analysts Set New Price Targets

Separately, Panmure Gordon reiterated a “buy” rating and set a GBX 56 target price on shares of Cambridge Cognition in a research report on Monday, January 19th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of GBX 56.

Cambridge Cognition Stock Performance

The firm has a market cap of £17.17 million, a PE ratio of -9.70 and a beta of 0.83. The firm has a 50-day moving average price of GBX 39.52 and a two-hundred day moving average price of GBX 34.50. The company has a quick ratio of 0.96, a current ratio of 0.40 and a debt-to-equity ratio of 28.66.

Cambridge Cognition (LON:COG) last released its earnings results on Monday, April 13th. The company reported GBX (3.90) earnings per share for the quarter. The firm had revenue of GBX 940 million during the quarter. Cambridge Cognition had a negative net margin of 17.82% and a negative return on equity of 62.89%. Research analysts forecast that Cambridge Cognition Holdings Plc will post 1.0293539 EPS for the current fiscal year.

About Cambridge Cognition

Cambridge Cognition Holdings Plc, a neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally. The company offers CANTAB digital cognitive assessment platform for drug development by enabling pharmaceutical companies to take new therapeutics from preclinical consultancy to pivotal studies and approval, as well as supports sponsors to enhance recruitment, develop safe and effective treatments, and enhance research and development efficiency.